Astrazeneca Plc (NYSE:AZN) Shorted Shares Decreased By 11.84%

December 7, 2017 - By Clifton Ray

 Astrazeneca Plc (NYSE:AZN) Shorted Shares Decreased By 11.84%

The stock of Astrazeneca Plc (NYSE:AZN) registered a decrease of 11.84% in short interest. AZN’s total short interest was 14.88 million shares in December as published by FINRA. Its down 11.84% from 16.88M shares, reported previously. With 3.58M shares average volume, it will take short sellers 4 days to cover their AZN’s short positions. The short interest to Astrazeneca Plc’s float is 0.6%.

The stock increased 0.41% or $0.13 during the last trading session, reaching $32.22. About 3.48 million shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since December 7, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $78.65 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 21.13 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

Among 24 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Monday, May 2 by Leerink Swann. The rating was upgraded by Credit Suisse to “Neutral” on Friday, May 12. As per Monday, April 10, the company rating was downgraded by Jefferies. The rating was initiated by Cantor Fitzgerald on Friday, February 26 with “Buy”. The stock has “Buy” rating by Bryan Garnier & Cie on Friday, September 18. The firm has “Hold” rating given on Monday, November 2 by Nordea. Credit Suisse downgraded AstraZeneca PLC (NYSE:AZN) on Tuesday, October 20 to “Underperform” rating. On Tuesday, January 19 the stock rating was upgraded by Barclays Capital to “Equal-Weight”. On Tuesday, January 26 the stock rating was upgraded by Oddo & Cie to “Top Pick”. The firm has “Buy” rating by Liberum Capital given on Friday, November 25.

More important recent AstraZeneca PLC (NYSE:AZN) news were published by: Investorplace.com which released: “AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment” on July 27, 2017, also Marketwatch.com published article titled: “AstraZeneca: FDA grants Imfinzi priority review”, Investorplace.com published: “AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success” on May 12, 2017. More interesting news about AstraZeneca PLC (NYSE:AZN) was released by: Investorplace.com and their article: “Why AstraZeneca plc (ADR) (AZN), Advanced Micro Devices, Inc. (AMD) and Spirit …” with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.